Literature DB >> 870273

Variations in the fate of triameterene.

A W Pruitt, J S Winkel, P G Dayton.   

Abstract

Triamterene is a pteridine used therapeutically as a diuretic. In order to better understand variations in effect and toxicity of triamterence in individuals, the fate of the drug in man was investigated. Both nonradioactive and 14C-labeled forms of the drug were administered, and specific methods of analysis were used to separate the parent compound from its metabolite. Individual variation in absorption, binding, and elimination was noted. The drug was excreted in bile as well as urine. Rapid and extensive metabolism of the agent occurred after oral and intravenous doses in healthy adult men. The peak plasma levels of the drug after an oral dose (200 mg) were under 0.3 microng/ml, but the concentration of the primary metabolite. (2,4,7-triamino-6-p-hydroxyphenylpteridine) was higher. The urinary excretion of the metabolite was at least three times that of the parent drug.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870273     DOI: 10.1002/cpt1977215610

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Diuretics. Clinical pharmacology and therapeutic use (Part I).

Authors:  A Lant
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 2.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

Review 3.  Drug interferences with plasma assays in therapeutic drug monitoring.

Authors:  S Yosselson-Superstine
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

4.  Pharmacokinetics of triamterene and its metabolite in man.

Authors:  J Hasegawa; E T Lin; R L Williams; F Sörgel; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

5.  Plasma and urinary levels of triamterene and certain metabolites after oral administration to man.

Authors:  U Gundert-Remy; D von Kenne; E Weber; H E Geissler; B Grebian; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

6.  Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.

Authors:  O Schuster; D Loew; H E Knoell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

7.  Effect of triamterene on tyrosine hydroxylase activity.

Authors:  P Steinberg; M C Rubio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

8.  [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].

Authors:  E Mutschler; H J Gilfrich; H Knauf; W Möhrke; K D Völger
Journal:  Klin Wochenschr       Date:  1983-09-15

9.  Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.

Authors:  H J Gilfrich; G Kremer; W Möhrke; E Mutschler; K D Völger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 10.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.